Associated Medical Professionals

Running trials

• Recruiting

  A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

  NCT07832292· Phase 2· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Source

• Recruiting

  Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

  NCT06800313· Phase 1/2· Source

• Active, not recruiting

  A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

  NCT06211764· Phase 3· Source

• Active, not recruiting

  A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

  NCT05884398· Phase 3· Source

• Active, not recruiting

  Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  NCT05316155· Phase 1/2· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

  NCT04640623· Phase 2· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

  NCT04497844· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer2 recruiting
• Bladder cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Source